abstract |
The present invention reports a newly-identified human blood bacterium (HBB), provides characterization, culturing and diagnostic methodologies therefor and methods for the treatment of pathophysiological states caused by the bacterium. The bacterium is apparently present in the bloodstream of all humans in very low numbers, and appears to be directly or indirectly associated with several diseases such as chronic fatigue syndrome, multiple sclerosis and other “autoimmune” diseases. Also provided are uses of engineered HBB. |